- Home
- Featured Publications
- Center Publications
- Management of Hypertension and High Low-Density Lipoprotein in Pediatric Type 1 Diabetes.
Management of Hypertension and High Low-Density Lipoprotein in Pediatric Type 1 Diabetes.
Citation | “Management Of Hypertension And High Low-Density Lipoprotein In Pediatric Type 1 Diabetes.”. The Journal Of Pediatrics, pp. 140-146.e12. . |
Center | Joslin Diabetes Center |
Author | Michelle L Katz, Zijing Guo, Lori M Laffel |
Keywords | anti-hypertensive, cholesterol, lipid-lowering |
Abstract |
OBJECTIVE: To evaluate hypertension and hyperlipidemia management patterns in youth with type 1 diabetes and to assess perceived effectiveness of management strategies and barriers to management. STUDY DESIGN: An electronic survey, including clinical scenarios, fielded to pediatric providers (members of the American Diabetes Association Diabetes in Youth Interest Group, Pediatric Endocrine Society, or T1D Exchange). RESULTS: Respondents (N = 207, 86% MDs, 68% female) were practicing clinicians for youth with type 1 diabetes. As an initial recommendation, the overwhelming majority of respondents (83%-99%) endorsed lifestyle and nonmedical recommendations (eg, improve glycemic control) for hypertension and hyperlipidemia. Yet, few (6%-17%) reported these recommendations as effective. Many respondents (57%) reported referring to another specialist for hypertension, whereas few (8%) reported referring to another specialist for hyperlipidemia management. Approximately one-fifth (21%) of respondents never initiate antihypertensive medications, whereas only 8% never initiate lipid-lowering medication. Among prescribers, the majority of respondents only started antihypertensive or lipid-lowering medications after persistent elevations and in the setting of either ineffective lifestyle or nonmedical interventions or additional cardiovascular risk factors. More than two-thirds of respondents endorsed medications as often effective for hypertension and hyperlipidemia (68% and 69%, respectively). CONCLUSIONS: Pediatric diabetes providers commonly defer prescribing antihypertensive and lipid-lowering medications until nonmedication interventions have been ineffective. Most providers describe medications, but not lifestyle interventions, as often effective. Efforts to align clinical practice with clinical guidelines are needed. |
Year of Publication |
2018
|
Journal |
The Journal of pediatrics
|
Volume |
197
|
Number of Pages |
140-146.e12
|
Date Published |
12/2018
|
ISSN Number |
1097-6833
|
DOI |
10.1016/j.jpeds.2017.11.059
|
Alternate Journal |
J. Pediatr.
|
PMID |
29395184
|
PMCID |
PMC6013061
|
Download citation |